Biogen IDEC Earnings Preview: Analysts Expect Falling Revenue Over Last Quarter

Biogen IDEC BIIB unveils its next round of earnings this Tuesday, July 26, 2011. Here is Benzinga's everything-that-matters guide for this Tuesday's second quarter earnings report.

Earnings and Revenue:

Analysts are predicting a positive EPS reading of $1.37 per share and revenues of $1.19 billion. Whether the reported numbers beat or miss analysts' estimates, they will also be compared against last year's numbers for the same period, which were a profit of $1.27 per share on revenues of $1.21 billion. We'll have to wait for Tuesday to see if Biogen IDEC falls in line with analyst expectations and reports an increase in EPS and a decline in revenue from the year-ago quarter.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

Quarter	Q1	Q4	Q3	Q2
EPS Estimate	$1.39	$1.23	$1.20	$1.08
EPS Actual	$1.42	$1.41	$1.33	$1.27

Stock Performance:

Shares of Biogen IDEC were trading at $104.37 as of July 20, 2011. Shares are up 55.7% year to date.

Average Stock Rating:

The average rating by analysts for Biogen IDEC is a Hold. Over the past three months this rating's strength has declined slightly.

Competitors:

Looking for a sympathy stock to trade or interested in the performance of other companies in the same sector? Take a look at some of Biogen IDEC's peers.

• Abbott Laboratories ABT: Hold with a $0.91 recent quarter EPS
• Amgen AMGN: Moderate Buy with a $1.32 recent quarter EPS
• Bristol-Myers Squibb BMY: Hold with a $0.58 recent quarter EPS

The medical-bioengineering company's industry has seen price/earnings growth of 4.2% during the current fiscal year.

Finally, a description of the company's main areas of operation: Biogen Idec is a global biotechnology company that meets the rising needs of therapeutic care providers and recipients.

Take Action:

Now that you're fully prepared, get ready to take quick action if the company reports any numbers significantly different from those listed above. Also, check back in with us after the announcement for a full recap and what-to-do-next guide.

• To see up-to-date news on Biogen IDEC, click here
• To see other trading ideas, click here
• To see other company earnings recaps, click here